Our 98 HD patients demonstrated a significantly lower ADAMTS13 activity than that of healthy subjects (41.0 ± 22.8% vs. 102.3 ± 17.7%, p < 0.001). This evidence concerns the gene ADAMTS13 and Huntington disease.